Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026

Genprex, Inc.

In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).
Data from 18 patients across Acclaim-1 (osimertinib), Acclaim-2 (pembrolizumab), and Acclaim-3 (atezolizumab) trials.
High (3+) Trop-2 expression showed near-significant correlation with PFS (p=0.053); will be further investigated as biomarker.
In SCLC patients, Trop-2 levels were universally low; no significant correlation with PFS observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.